Welcome to the Hemodialysis Novel Therapies (HDNT) Consortium website.

The Hemodialysis Novel Therapies (HDNT) Consortium was established by the National Institutes of Diabetes, Digestive, and Kidney Diseases (NIDDK) to design and conduct pilot and feasibility studies of novel therapies to reduce morbidity and mortality for patients treated with maintenance hemodialysis. The consortium is a partnership between participating clinical centers, the data coordinating center (DCC) at the University of Pennsylvania and the NIDDK. The treatments being evaluated by the HDNT Consortium include drugs that have been in use for many years, dietary supplements, and new biologic agents that target specific inflammatory mediators. The goal of this collaborative group is conduct studies that will provide the necessary information to move the evaluation of promising interventions from early phase studies to large-scale clinical trials that will ultimately improve outcomes for patients treated with maintenance hemodialysis.